ArticleScientific reports2025
Bioinspired synthesis of ultra-small copper-aspartate BioMOF nanodots using sodium caseinate for targeted curcumin delivery.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, an attempt was made to create of copper-aspartate (Cu-Asp) biological metal organic framework (bioMOF), inspired by the process of bio-mineralization. Ultra-small nanodots of biocompatible Cu-Asp was synthesized as a carrier for curcumin (CCM) in the presence of sodium caseinate (CAS) in an aqueous medium at room temperature. Synthesis was performed in the presence of different amounts of CCM (10, 15, and 20 mg). Two different morphologies of the nanorod and nanodots (for the first time) were obtained. To target the drug delivery processes, the folic acid (FA) factor was used during the synthesis of ultra-samll nanodots. X-ray diffraction, scanning and field emission scanning (SEM and FESEM) and transmission electron microscopies, Fourier transform infrared (FT-IR), UV-Vis, and Thermogravimetric (TG) analyses were performed to characterize the synthesized nanostructures. The drug loading efficiency and capacity percentages for CAS/CCM/FA@Cu-Asp (5.1 and 74%, respectively) indicated that the encapsulation of the drug was appropriate. In addition, the rate of drug release at different pH values was investigated, and the results showed different performances of the nanocarriers at pH = 5.5, 6.8, and 7.4. The release of CCM from CAS/CCM@Cu-Asp was 60% at pH = 5.5 after 3 days. At pH 7.4, only 10% CCM was released after 4 h and remained nearly stable. The potential cytotoxicity was evaluated using the MTT assay in Normal skin fibroblast and HeLa (positive folate receptor cancer cell) cell lines. The highest SI was observed for CAS/CCM/FA@Cu-Asp (2.15).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.